JW Jungwoo Launches Korea's First 200ml-Class Comprehensive Nutritional Infusion

JW Pharmaceutical's total parenteral nutrition (TPN) 'Winnerferi Injection' 217ml and 241ml (Photo by JW Pharmaceutical)

[Asia Economy Reporter Chunhee Lee] JW Pharmaceutical announced on the 17th that it has launched the first 200ml-class Total Parenteral Nutrition (TPN) in Korea and has begun marketing activities.

The newly released products are ‘Winnerfperi Injection’ 217ml and 241ml, which are peripheral venous TPN solutions. Winnerfperi Injection 217ml is a non-reimbursed TPN with a dosing time approximately 50 minutes shorter than the existing small-volume TPN (362ml). For a patient weighing 60kg, it can be administered in 72 minutes at the maximum infusion rate. The formulation consists of four types of lipids including omega-3 fatty acids, amino acids, and glucose, providing balanced nutrients. It also offers 1.5 to 3 times more calories compared to a 250ml amino acid-only preparation.

Winnerfperi Injection 241ml is a reimbursed TPN for outpatient care or cancer day ward patients. Until now, all reimbursed TPN products released were 500ml or larger, and due to insufficient infusion time for outpatients with short hospital stays, amino acid-only preparations were often prescribed instead of TPN. However, Winnerfperi Injection 241ml can be administered in 1 hour and 20 minutes for a 60kg patient, making outpatient prescriptions possible. It supplies balanced nutrients to cancer patients at high risk of malnutrition, and when special medical expense coverage is applied, the patient’s out-of-pocket cost is in the 800 won range, reducing the economic burden.

Winnerf is JW Pharmaceutical’s third-generation TPN brand that maintains separated chambers during storage and transport and mixes the components by breaking the chambers before administration. It consists of four lipid components?refined fish oil (20%), refined soybean oil (30%), olive oil (25%), and MCT (25%)?as well as glucose and amino acids. With a high omega-3 content, it is excellent for enhancing immunity and promoting recovery. Since 2019, JW Life Science has been exporting this product under the name ‘Pinomel Injection’ to Europe and global markets through Baxter, the world’s largest infusion company based in the United States.

Winnerfperi Injection 217ml and 241ml are produced at JW Life Science’s infusion factory TPN Line 3 in the Dangjin production complex, Chungnam. TPN Line 3 is the only dedicated TPN production facility in Korea capable of producing all volumes from medium and large volumes over 1000ml to small volumes around 200ml.

?

A JW Pharmaceutical official stated, “Reflecting the abundant demand for small-volume 3-chamber TPN, we launched the 200ml-class TPN,” and added, “As a leader in the infusion market, we will continue to develop excellent infusion products for patients.”

This content was produced with the assistance of AI translation services.